Are Polycythemia and Polycythemia Vera the Same Thing?

Polycythemia and polycythemia vera are not the same thing, though the terms are frequently confused and sometimes used interchangeably in casual conversation. Polycythemia is a broad umbrella term meaning “too many red blood cells,” and it covers a wide range of conditions with very different causes and outlooks. Polycythemia vera is one specific and relatively rare disease under that umbrella, driven by a genetic mutation in the bone marrow. Understanding the distinction matters because treatment, monitoring, and long-term risk differ enormously depending on which type of polycythemia a person actually has.

What “Polycythemia” Actually Means

At its simplest, polycythemia refers to a higher-than-normal concentration of red blood cells in the bloodstream. That elevated concentration can show up on routine lab work as a high hemoglobin level or a high hematocrit (the percentage of blood volume occupied by red blood cells). But a high reading on those tests does not automatically mean the body is producing too many red cells. Sometimes the red cell count is genuinely elevated. Other times, the blood just appears more concentrated because there is less liquid (plasma) surrounding the cells.

This is the first major fork in the road. Doctors separate polycythemia into two broad categories: absolute polycythemia, where the body truly is making more red blood cells than normal, and relative polycythemia, where the red cell mass is actually normal but the plasma volume has shrunk, making everything look more concentrated.¹ Dehydration is a classic cause of relative polycythemia. Someone who shows up at a lab severely dehydrated can have a hematocrit reading that looks alarming but normalizes once they drink enough fluids.²

Absolute polycythemia then splits again. If the bone marrow itself is overproducing red cells due to an internal defect, that is primary polycythemia. If the bone marrow is being driven to overproduce by an outside signal, most commonly excessive erythropoietin (EPO), that is secondary polycythemia.³ Polycythemia vera falls squarely into the primary category. It is the most well-known primary polycythemia, but it is far from the only reason a person’s red cell count can be elevated.

What Sets Polycythemia Vera Apart

Polycythemia vera is classified as a myeloproliferative neoplasm, which is a formal way of saying it is a type of blood cancer in which the bone marrow grows cells in an uncontrolled fashion.⁴ In the vast majority of cases, the culprit is a mutation in a gene called JAK2. About 95% of people with polycythemia vera carry a specific JAK2 mutation (known as V617F), which causes a signaling protein in blood-forming cells to stay switched on when it should turn off.⁵ The result is that the bone marrow churns out red blood cells regardless of whether the body needs them.

Because the bone marrow is acting on its own, the body’s normal feedback loop gets inverted. Under normal circumstances, when oxygen levels drop, the kidneys release EPO to tell the bone marrow to make more red cells. In polycythemia vera, the marrow is already overproducing, so all those extra red cells deliver plenty of oxygen, and EPO levels actually fall below normal.⁶ That suppressed EPO level is one of the clearest signals that a person’s polycythemia is primary rather than secondary.

A formal diagnosis of polycythemia vera under current guidelines requires hemoglobin above 16.5 g/dL (or hematocrit above 49%) in men, or above 16 g/dL (hematocrit above 48%) in women, combined with a positive JAK2 mutation test. Bone marrow biopsy showing characteristic overgrowth of blood-forming cells adds further confirmation.⁷ Without the JAK2 mutation or equivalent molecular evidence, doctors look very carefully for other explanations before labeling someone with polycythemia vera.

Secondary Polycythemia and Its Many Triggers

Secondary polycythemia is far more common than polycythemia vera, and it works through a completely different mechanism. Here, the bone marrow is healthy and responding appropriately (or at least predictably) to signals from the rest of the body. The most frequent trigger is chronic hypoxia. When the body does not get enough oxygen over a prolonged period, the kidneys ramp up EPO production, and the bone marrow dutifully produces more red blood cells in an attempt to compensate.⁸

Conditions that cause this kind of chronic oxygen shortage include severe chronic obstructive pulmonary disease (COPD), obstructive sleep apnea, certain congenital heart defects, and living at very high altitudes for extended periods. The polycythemia in these cases is the body doing what it is supposed to do in the face of low oxygen. It is an appropriate response that can still cause problems if it goes too far, since thicker blood raises the risk of clotting.⁸

There are also “inappropriate” causes of secondary polycythemia, where EPO is elevated for reasons that have nothing to do with oxygen levels. Testosterone replacement therapy is one well-recognized trigger. Certain tumors, particularly some kidney and liver cancers, can secrete EPO on their own, pushing red cell production upward. In all these cases, EPO levels tend to be normal or high, which is the opposite of what you see in polycythemia vera.⁶

Relative Polycythemia and Gaisböck Syndrome

Relative polycythemia is a different situation entirely. The red cell mass is normal. What has changed is the volume of plasma in the blood. When plasma volume contracts, the same number of red cells becomes more concentrated, and lab tests show a high hematocrit even though the marrow has done nothing unusual.¹ This can happen acutely with dehydration, diuretic use, or burns. It can also persist as a chronic state.

The chronic version has historically been called Gaisböck syndrome, after a physician who described it in 1905. The classic profile is an overweight, hypertensive man, often a smoker, with a ruddy complexion and elevated hematocrit but no true increase in red cell mass.⁹ For decades, this was called “stress polycythemia,” but the relationship to psychological stress is not well supported. The more consistent associations are with obesity, smoking, alcohol use, and certain blood pressure medications.⁹

Gaisböck syndrome is worth knowing about because it can initially look similar to early polycythemia vera on basic labs. The patient has a high hematocrit, may feel lousy, and might even have some cardiovascular issues. But the underlying cause and the appropriate management are entirely different. Treating someone for a bone marrow neoplasm when they actually have contracted plasma volume from smoking and dehydration would be a serious mistake.

How Doctors Tell the Types Apart

The diagnostic workup generally follows a logical sequence. When a high hematocrit or hemoglobin shows up, the first step is ruling out relative polycythemia. If the patient is clearly dehydrated or on diuretics, repeating the test after rehydration often solves the puzzle. For persistent elevations, a serum EPO level is one of the most informative single tests. A low EPO points toward a primary marrow problem like polycythemia vera. A normal or high EPO suggests the marrow is being stimulated from outside, pointing toward secondary causes.⁶

If polycythemia vera is suspected, testing for the JAK2 mutation is the next step. A positive result in a patient who meets the hemoglobin and hematocrit thresholds essentially clinches the diagnosis. When JAK2 is negative (which happens in a small minority of PV cases), additional molecular testing and a bone marrow biopsy become more important.⁵ For suspected secondary polycythemia, the workup shifts toward identifying the source of excess EPO. That might involve overnight oxygen monitoring for sleep apnea, pulmonary function testing, or imaging to look for EPO-secreting tumors.

Why Treatment Looks Completely Different

This is where the practical stakes of the distinction become most obvious. In polycythemia vera, the bone marrow will keep overproducing red cells indefinitely, so treatment focuses on keeping the blood thin enough to prevent clots and managing the disease long-term. The standard approach includes regular phlebotomy (blood removal) to keep the hematocrit below 45%, along with daily low-dose aspirin. Patients at higher risk of clotting, particularly those over 60 or with a history of blood clots, often receive additional medication to slow the marrow down. Hydroxyurea and interferon are the most common choices for this cytoreductive therapy.¹⁰

In secondary polycythemia, the entire treatment philosophy is different. The goal is to address whatever is driving the excess EPO. For someone with COPD or sleep apnea, that means optimizing oxygen delivery through supplemental oxygen, CPAP machines, or other respiratory interventions. For testosterone-induced erythrocytosis, it may mean reducing the dose or temporarily stopping treatment.¹¹ Importantly, routine phlebotomy is not recommended for most secondary polycythemia the way it is for polycythemia vera. There is no clear evidence that the clotting risk is elevated in the same way, and removing red cells from someone whose body is making them for a reason (to compensate for low oxygen) can actually worsen tissue oxygen delivery.¹²

When phlebotomy is used for secondary polycythemia, it is typically reserved for cases with very high hematocrits (generally above 56%) or symptoms of blood thickness like severe headaches and visual changes, and the target is less aggressive than in polycythemia vera, often aiming for a hematocrit around 50-52% rather than below 45%.¹² Even then, there is a real risk of tipping the patient into iron deficiency anemia. One study of patients undergoing therapeutic phlebotomy for secondary polycythemia found that roughly 37% developed anemia after ten procedures, creating a cycle where the resulting low iron triggers further abnormal red cell production.¹³

Thrombosis Risk in Polycythemia Vera

Blood clots are the most feared complication of polycythemia vera, and the risk is substantially higher than in other blood disorders in the same family. A large retrospective analysis from Sweden found that within three months of diagnosis, patients with polycythemia vera had roughly a three-fold higher risk of arterial clots (such as heart attacks and strokes) and about a thirteen-fold higher risk of venous clots compared to matched controls.¹⁴ Over 20 years, roughly a quarter of polycythemia vera patients experience a blood clot.⁷

This elevated clotting risk is one of the reasons the hematocrit target in polycythemia vera (below 45%) is so strict. It is also why aspirin and, for higher-risk patients, cytoreductive drugs are standard parts of the treatment plan. The clotting risk in secondary polycythemia is less clear-cut. Chronic hypoxia with very high hematocrits can increase blood viscosity and lead to clots, but the evidence for a uniform clotting risk across all forms of secondary polycythemia is not as strong.¹¹

The Symptom Burden of Polycythemia Vera

People often assume that polycythemia vera is a “mild” blood cancer because median survival is around 15 years (and exceeds 35 years for those diagnosed under age 40).⁷ But survival numbers do not capture day-to-day quality of life. The REVEAL study, a large observational study of over 2,000 polycythemia vera patients in the United States, found that about 80% experienced atigue, roughly 61% reported early satiety (feeling full after eating very little), and around 58% described difficulty staying active.¹⁵ These symptoms persisted regardless of how well blood counts were controlled, suggesting that they are part of the disease’s underlying biology rather than simply a consequence of high hematocrit.¹⁶

One of the more distinctive symptoms is aquagenic pruritus, an intense itching triggered by contact with water. It can happen during a shower, after swimming, or even from sweating. Studies of patients with confirmed polycythemia vera have found that between 40% and 68% experience this symptom, and in more than half of those affected, the itching begins before the diagnosis is ever made.¹⁷ ¹⁸ Patients typically describe the itching as worst on the trunk and upper limbs, and it can range from mild annoyance to a profoundly disruptive condition that leads people to avoid bathing. Standard antihistamines often do not help much. For patients who have tried other options without relief, ruxolitinib, a JAK inhibitor, has shown benefit in alleviating both pruritus and spleen enlargement.¹⁰

Inherited Forms of Polycythemia

There is yet another category that does not fit neatly into either polycythemia vera or secondary polycythemia: congenital (inherited) polycythemias. These are rare genetic conditions in which a person is born with mutations that affect how the body senses or responds to oxygen. The best-known example is Chuvash polycythemia, first identified in an ethnic group from the Chuvash Republic in Russia but since found in families of various ancestries around the world.¹⁹

In Chuvash polycythemia, a mutation in the VHL gene disrupts the body’s oxygen-sensing pathway. The VHL protein normally helps degrade a molecule called HIF (hypoxia-inducible factor) when oxygen levels are adequate. With the Chuvash mutation, HIF sticks around longer than it should, tricking the body into behaving as if it is chronically oxygen-deprived even when oxygen levels are perfectly fine. The kidneys ramp up EPO, and the marrow makes extra red cells in response.¹⁹ Unlike polycythemia vera, there is no JAK2 mutation and no risk of the marrow transforming into a more aggressive cancer. Unlike typical secondary polycythemia, there is no external lung or heart problem to fix. Management is its own challenge and does not follow the same playbook as either PV or standard secondary polycythemia.

Other inherited mutations affecting the EPO receptor or hemoglobin’s ability to release oxygen also exist. These are individually very rare but collectively they represent a reminder that “polycythemia” is not one disease. It is a lab finding with an entire family tree of possible explanations, and polycythemia vera is only one branch.

When the Lines Get Blurry in Practice

In a textbook, these categories are neat. In real patients, they sometimes overlap. A longtime smoker with COPD can develop secondary polycythemia from chronic low oxygen, and they could, independently and unluckily, also acquire a JAK2 mutation and develop polycythemia vera. When both conditions coexist, the usual diagnostic clues become muddled. EPO levels that should be low in PV may be pushed upward by hypoxia, and a hematocrit that would normally be attributed to lung disease may actually be partly driven by a clonal marrow disorder. This is one reason bone marrow biopsy remains useful even in the era of molecular testing: it can reveal the characteristic marrow overgrowth of polycythemia vera in a patient whose clinical picture is clouded by coexisting conditions.

Patients sometimes receive a vague diagnosis of “polycythemia” and remain uncertain about which type they have. If you have been told you have polycythemia but have never been tested for JAK2 or had your EPO level checked, it is worth asking your doctor to clarify. The distinction between a bone marrow cancer that requires lifelong management and a secondary condition that resolves when the underlying cause is treated is not academic. It shapes everything from how often you need blood draws to whether you should be on aspirin to what your long-term outlook realistically looks like.

1
PubMed. The contracted plasma volume syndromes (relative polycythaemias) and their haemorheological significance
2
PubMed. Polycythemia Vera: The Packed Cell Volume and The Curious Logic of The Red Cell Mass
3
PubMed Central. Erythrocytosis Following Testosterone Therapy
4
PubMed. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management
5
PubMed Central. Impact of World Health Organization (WHO) Revised Criteria-2016 on the Diagnosis of Polycythemia Vera
6
Mayo Clinic Proceedings. Reassessing the Evaluation of Polycythemia: The Role of Serum Erythropoietin Levels and Endogenous Erythroid Colonies
7
PubMed. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management
8
PubMed Central. Secondary polythaemia from chronic hypoxia is a risk for cerebral thrombosis: a case report
9
PubMed. Gaisbock Syndrome: A Review of Contemporary Studies, Pathogenesis, Complications, and Possible Treatment
10
JAMA. Diagnosis and Treatment of Polycythemia Vera: A Review
11
CMAJ. Investigation and management of erythrocytosis
12
PubMed Central. Successful use of phlebotomy to treat severe secondary polycythemia due to chronic lung disease
13
Blood. Anemia in Patients Undergoing Therapeutic Phlebotomy for Polycythemia Secondary to COPD and OSA
14
SpringerOpen / Annals of Hematology. Thromboembolic events in polycythemia vera
15
PubMed Central. Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
16
Clinical Lymphoma Myeloma and Leukemia. Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study
17
PubMed. Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics
18
PubMed. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients
19
Blood. Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry